Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BD03 DNA Vaccine for CMV and BKV Prevention in Kidney Transplant Recipients
NCT03576014Phase 1Unknown
- Start
- Apr 2018
- Primary completion
- Jan 2019
- Modality
- Prophylactic Vaccines, DNA Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of BD03 in cytomegalovirus infection (CMV) and BK virus infection (3 arms). Primary endpoint: Dose-Limiting Toxicities at 5 weeks. Status: unknown.
02
Drugs
BD03
03
Conditions
cytomegalovirus infection (CMV)BK virus infection
Beyond the preview
Go deeper on NCT03576014.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03576014.